# AmerisourceBergen Corporation – Consensus ‘buy’ rating and 16.2% Upside Potential

- Link: https://www.directorstalkinterviews.com/amerisourcebergen-corporation-consensus-buy-rating-and-16.2-upside-potential-5/4121129267
- Published: 2023-10-12T13:21:05+01:00
- Author: Charlotte Edwards

**AmerisourceBergen Corporation** with ticker code (ABC) have now 14 market analysts
covering the stock. The analyst consensus now points to a rating of ‘buy’. The range
between the high target price and low target price is between 225 and 190 suggesting
an average Analsyt target price of $209.57. Given that the stocks previous close
was at $180.39 and the analysts are correct then there would likely be a percentage
uptick in value of 16.2%. It’s also worth noting that there is a 50 day moving average
of $181.99 and the 200 day moving average is $172.18. The company has a market capitalization
of 36.15B. The current share price for the company is: 179.98 USD

 The potential market cap would be $41,997,301,323 based on the market consensus.

The company has a dividend yield of 1.09%. Other points of data to note are a P/
E ratio of 21.92, revenue per share of 1247.29 and a 2.7% return on assets.

AmerisourceBergen Corporation is a global pharmaceutical sourcing and distribution
services company. The Company’s U.S. Healthcare Solutions segment distributes an
offering of brand-name, specialty brand-name and generic pharmaceuticals, over-the-
counter healthcare products, home healthcare supplies and equipment, and related
services to a wide variety of healthcare providers, including acute care hospitals
and health systems, independent and chain retail pharmacies, mail order pharmacies,
medical clinics, long-term care and alternate site pharmacies, and other customers.
The International Healthcare Solutions segment consists of businesses that focus
on international pharmaceutical wholesale and related service operations and global
commercialization services. This segment consists of Alliance Healthcare, World 
Courier, Innomar, Profarma, and Profarma Specialty. The Company also focuses on 
specialty services and a global platform of pharma manufacturer services capabilities.

Share on: